ArticleMedicine2025
The kinetic parameters of dynamic contrast-enhanced MRI with ultrafast imaging in breast cancer patients receiving neoadjuvant chemotherapy: Prediction of pathologic complete response and correlation with histologic microvessel density.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrafast Breast MRI: A Narrative Review.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early prediction of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer patients can help forecast prognosis and guide decisions on adjuvant therapy. This study aimed to determine whether the kinetic parameters of dynamic contrast-enhanced MRI (DCE-MRI) with ultrafast imaging can predict pCR following NAC in breast cancer patients and whether these parameters are correlated with histologic microvessel density (MVD). In this retrospective study, 61 breast cancer patients who underwent NAC and surgery between August 2020 and 2022 were analyzed. Ultrafast and conventional DCE-MRI features, along with pathologic results, were compared between the pCR and non-pCR groups. Regression analysis was conducted to identify predictive factors for pCR. Additionally, MRI kinetic parameters were correlated with histologic MVD. Of the 61 patients, 17 (27.9%) achieved pCR. The pCR group exhibited a larger delayed washout component (P = .002) and a smaller angiovolume (P = .02) compared to the non-pCR group; however, these factors lost significance when accounting for tumor size, lymph node status, and molecular subtypes. In a subgroup analysis based on molecular subtype, a low initial enhancement value (≤362.5%) and angiovolume (≤10.3 cc) predicted pCR in human epidermal growth factor receptor 2-enriched breast cancer, with an area under the curve of 0.833. The maximum slope on ultrafast MRI was higher in the high MVD group compared to the low MVD group (P = .049). Human epidermal growth factor receptor 2-enriched breast cancer with low vascularity on DCE-MRI is more likely to achieve pCR, although MRI kinetic parameters were not independent predictors of pCR in all breast cancer subtypes. The maximum slope on ultrafast MRI was the only kinetic parameter that correlated with histologic MVD. Larger studies focused on molecular subtypes are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.